Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 7/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7128244 | 1.00 | AOC3 (0.43) | AOC3CD274ITGB3ITGA2BHRH3 | |
| SCHEMBL7128241 | 1.00 | AOC3 (0.43) | AOC3CD274ITGB3ITGA2BHRH3 | |
| SCHEMBL7121552 | 0.78 | CD274 (0.47) | AOC3CD274ITGB3ITGA2BHRH3 | |
| SCHEMBL7121540 | 0.78 | CD274 (0.46) | AOC3CD274ITGB3ITGA2BHRH3 | |
| SCHEMBL7130448 | 0.76 | HRH3 (0.51) | AOC3CD274ITGB3ITGA2BHRH3 | |
| SCHEMBL8192685 | 0.72 | CYP26A1 (0.45) | CD274 | |
| SCHEMBL8192688 | 0.72 | CYP26A1 (0.45) | CD274 | |
| SCHEMBL8200806 | 0.72 | CYP26A1 (0.45) | CD274 | |
| SCHEMBL8200352 | 0.71 | CD274 (0.47) | CD274 | |
| SCHEMBL8203686 | 0.71 | CD274 (0.47) | CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114438-A1 | Lactam derivatives as antiarrhythmic agents | S ATWAL KARNAIL (US) | 2003-06-19 | — | — | US | claimed |
| US-6262068-B1 | ISOQUINOLONES | BRISTOL-MYERS SQUIBB COMPANY | 2001-07-17 | — | — | US | claimed |
| US-6664250-B2 | Cardiovascular disorders | BRISTOL-MYERS SQUIBB CO. | 2003-12-16 | — | — | US | disclosed |
| US-6262068-B1 | ISOQUINOLONES | BRISTOL-MYERS SQUIBB COMPANY | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114438-A1 | Lactam derivatives as antiarrhythmic agents | NPR3, SCN3A, NRDC | AOC3 11/4885CD274 3287/4885ITGB3 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.